[PRESS RELEASE]
Dopharma and Ripac-Labor announce Ground-breaking Ceremony for new Autogenous Vaccine Production Facility in Potsdam
Raamsdonksveer, Netherlands / Potsdam, Germany, 28 February 2025 – The Dopharma Group and its fully owned subsidiary Ripac-Labor GmbH, are pleased to announce the official ground-breaking of their new state-of-the-art production facility for autogenous vaccines in Potsdam, Germany. This took place in the presence of Mike Schubert (Lord mayor of Potsdam), Wijnand de Bruijn (CEO Business Dopharma Group) and Heiko Rüdiger (CEO Ripac-Labor) last Friday. With is this ceremony, the first mark of the project has been completed.
This milestone marks a significant step in the companies’ strategic expansion and commitment to meeting evolving regulatory standards. The new facility is designed to comply with upcoming Good Manufacturing Practices (GMP) regulations expected to be implemented across the European Union.
Ahead of European legislation
While the EU’s regulatory timeline has recently experienced delays, the Dopharma group and Ripac-Labor remain committed to proactively investing in the future of veterinary biologicals by moving forward with the initial phase of this ambitious project.
‘It’s important to keep investing in the future, regardless the timeline of the EU. The Dopharma Group strongly believes that autogenous vaccines will play an important part of livestock farming as it focusses on prevention, completing the toolbox of veterinarians to keep animals healthy’, emphasizes Wijnand de Bruijn, CEO Business of the Dopharma Group.
The facility will increase production capacity and improve efficiency of autogenous vaccines, ensuring continuous delivery of high-quality, tailored solutions for veterinarians and farmers. This investment underscores the company’s dedication to innovations, animal health, and sustainable farming practices.
Ripac-Labor the perfect partner for autogenous vaccines and diagnostics
Through the years, Ripac-Labor has proven to be a trustworthy partner for diagnostics and autogenous vaccines in Europe. Being a part of the Dopharma Group, the investment in knowledge and expertise are secured, with this ground-breaking ceremony as prove of this commitment.
‘We are very pleased with the developments we have been through the last couple of years. Thanks to the good relationships with the city of Potsdam, our architect and the support of the Dopharma Group, we can celebrate today’s milestone and show our believe in Potsdam as place for innovation’, concludes Heiko Rüdiger, CEO Ripac-Labor.
For media inquiries, please contact: [email protected].
About Ripac-Labor GmbH
Ripac-Labor GmbH, a fully owned subsidiary of Dopharma International B.V., specializes in veterinary services and the production of autogenous vaccines for livestock. These customized vaccines provide targeted protection against farm-specific pathogens, offering a crucial tool for disease prevention and control. The expansion of Ripac-Labor’s production capabilities further strengthens the Dopharma group’s position in the European veterinary market.
The company currently employs 48 academic specialists, experienced laboratory technicians, and other well-trained staff.
About the Dopharma Group
Dopharma is a family-owned pharmaceutical company dedicated to producing and supplying high-quality veterinary pharmaceuticals for livestock since 1969. With 95% of its veterinary pharmaceuticals manufactured in-house at its GMP-certified production facilities, Dopharma ensures strict quality control and continuous innovation. The company’s mission is to provide smart, science-driven solutions that support the health and productivity of livestock worldwide.
